Esketamine: uncertain safety and efficacy data in depression

Br J Psychiatry. 2021 Nov;219(5):621-622. doi: 10.1192/bjp.2021.163.

Authors

Mark Horowitz¹, Joanna Moncrieff²

Affiliations

¹ Clinical Research Fellow, University College London, London, UK. Email: mark_horo@hotmail.com.
² Professor of Critical and Social Psychiatry, University College London, London, UK.

PMID: 35048830
DOI: 10.1192/bjp.2021.163

No abstract available

Publication types

Comment

MeSH terms

Depression / drug therapy
Depressive Disorder, Treatment-Resistant* / drug therapy
Humans
Ketamine* / adverse effects

Substances

Esketamine
Ketamine